AU2022299196A1 - Method to control administration of active substance to the digestive tract - Google Patents

Method to control administration of active substance to the digestive tract Download PDF

Info

Publication number
AU2022299196A1
AU2022299196A1 AU2022299196A AU2022299196A AU2022299196A1 AU 2022299196 A1 AU2022299196 A1 AU 2022299196A1 AU 2022299196 A AU2022299196 A AU 2022299196A AU 2022299196 A AU2022299196 A AU 2022299196A AU 2022299196 A1 AU2022299196 A1 AU 2022299196A1
Authority
AU
Australia
Prior art keywords
active substance
digestive tract
control administration
administration
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022299196A
Other languages
English (en)
Inventor
Aouatef Bellamine
Shane Durkee
Tyler White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Greenwood LLC
Original Assignee
Lonza Greenwood LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Greenwood LLC filed Critical Lonza Greenwood LLC
Publication of AU2022299196A1 publication Critical patent/AU2022299196A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022299196A 2021-06-24 2022-06-23 Method to control administration of active substance to the digestive tract Pending AU2022299196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214438P 2021-06-24 2021-06-24
US63/214,438 2021-06-24
PCT/US2022/034683 WO2022271922A1 (en) 2021-06-24 2022-06-23 Method to control administration of active substance to the digestive tract

Publications (1)

Publication Number Publication Date
AU2022299196A1 true AU2022299196A1 (en) 2023-12-21

Family

ID=84544830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022299196A Pending AU2022299196A1 (en) 2021-06-24 2022-06-23 Method to control administration of active substance to the digestive tract

Country Status (8)

Country Link
US (1) US20240285699A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340819A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526149A (cg-RX-API-DMAC7.html)
CN (1) CN117479929A (cg-RX-API-DMAC7.html)
AU (1) AU2022299196A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023027371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223905A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022271922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270523B (zh) * 2023-05-15 2023-08-08 四川厌氧生物科技有限责任公司 一种耐酸的口服双层胶囊及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667167C (en) * 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
BR112012006651B1 (pt) * 2009-09-24 2021-11-03 Capsugel Belgium Nv Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc
DE102010022174A1 (de) * 2010-05-12 2011-11-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP3028694B1 (en) * 2014-12-02 2017-07-12 Capsugel Belgium NV Dosage form articles for delayed release
EP3882259B1 (en) * 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US20190388344A1 (en) * 2018-06-22 2019-12-26 Probiotech Llc Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor
US20200038215A1 (en) * 2018-08-01 2020-02-06 Ethicon, Inc. Transient implantable device to control absorption of nutrients
US12144834B2 (en) * 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CA3117956A1 (en) * 2018-10-30 2020-05-07 Vitabolus Inc. Oral delivery of therapeutic mammalian cells
MX2022004515A (es) * 2019-10-16 2022-07-12 Capsugel Belgium Nv Metodo y composicion para aumentar la sintesis de proteinas musculares.

Also Published As

Publication number Publication date
CA3223905A1 (en) 2022-12-29
BR112023027371A2 (pt) 2024-03-12
JP2024526149A (ja) 2024-07-17
CN117479929A (zh) 2024-01-30
EP4340819A4 (en) 2025-04-02
WO2022271922A1 (en) 2022-12-29
EP4340819A1 (en) 2024-03-27
US20240285699A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2017171535A3 (en) Compositions
EP4327797A3 (en) Multi phase soft gel capsules, apparatus and method thereof
AU2016219653A1 (en) Crystallization Method and Bioavailability
WO2011127302A3 (en) Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011149877A8 (en) Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
WO2011152809A3 (en) Effervescent formulations comprising cephalosporin and clavulanic acid
EP4133990A4 (en) METHOD AND SYSTEM FOR CONTROLLING A CAPSULE ENDOSCOPE
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
EP4363444A4 (en) ADMINISTRATION OF ANTI-HPA-1A ANTIBODIES
EP3873538A4 (en) ORAL DELIVERY OF THERAPEUTIC MAMMALIAN CELLS
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2007147043A3 (en) Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery
TW200602090A (en) Antibiotic-based pharmaceutical formulation in microcapsular form
WO2012063005A3 (fr) Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
EP4297741A4 (en) METHODS AND FORMULATIONS FOR TOPICAL ADMINISTRATION OF GABAPENTINOIDS
PT3768244T (pt) Formulação de libertação instestinal de uma enzima digestiva, método de preparação e preparação galénica
BR112023027371A2 (pt) Método para controlar administração de substância ativa ao trato digestivo
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2007062335A8 (en) New pleuromutilin derivative and its use
HK40112715A (en) Dosage form for improving palatability of drug substance
HK40111254A (en) Administration of c5-binding proteins
HK40116574A (en) Transdermal therapeutic system for the transdermal administration of selexipag